12 September 2023: Original Paper
Living Donor Liver Transplantation in Patients with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies Using Preoperative Desensitization Therapy According to Intensity of Donor-Specific Antibodies: A Single-Center Study
Kohei Ogawa ABCDEF* , Kei Tamura AB , Katsunori Sakamoto C , Naotake Funamizu B , Masahiko Honjo B , Mikiya Shine B , Yusuke Nishi B , Tomoyuki Nagaoka B , Chihiro Ito B , Miku Iwata B , Mio Uraoka B , Yasutsugu Takada ADDOI: 10.12659/AOT.941346
Ann Transplant 2023; 28:e941346
Figure 3 Changes in mean fluorescence intensity (MFI) of anti-human leucocyte antigen (HLA) antibody and the clinical course of case 2 (Microsoft, PowerPoint for Mac, ver. 16.48). (A) Pre- and post-transplant anti-HLA antibodies. Pre-Transplantation; on admission (before rituximab administration) and just before liver transplantation (LT) (after rituximab administration). After transplantation; on postoperative day (POD) 7 and 6 months after LT. (B) Clinical course of case 2. Serum bilirubin levels increased from POD 5, but improved with steroid pulse therapy. Serum transaminases increase from POD 15, but improved with repeated steroid pulse therapy. DSA – donor-specific anti-human leukocyte antigen antibody; CREG – cross-reactive epitope group; AST – aspartate transaminase; ALT – alanine transaminase; T-Bil – total bilirubin, D-Bil – direct bilirubin.